ASXL1 Polyclonal antibody
ASXL1 Polyclonal Antibody for WB, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human
Applications
WB, ELISA
Conjugate
Unconjugated
Cat no : 16803-1-AP
Synonyms
Validation Data Gallery
Tested Applications
Positive WB detected in | HeLa cells, K-562 cells, MCF-7 cells |
Recommended dilution
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:500-1:2000 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Product Information
16803-1-AP targets ASXL1 in WB, ELISA applications and shows reactivity with human samples.
Tested Reactivity | human |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | ASXL1 fusion protein Ag10290 相同性解析による交差性が予測される生物種 |
Full Name | additional sex combs like 1 (Drosophila) |
Calculated molecular weight | 84aa,10 kDa; 1541aa,165 kDa |
Observed molecular weight | ~200 kDa |
GenBank accession number | BC064984 |
Gene symbol | ASXL1 |
Gene ID (NCBI) | 171023 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
Additional sex combs-like 1 (ASXL1) is a member of the ASXL family, which is involved in epigenetic regulation. It is one of the mammalian Asx homologs. Mutations in the ASXL1 gene are frequently found in myeloid neoplasms, breast cancers and prostate cancers (PMID: 30013160; PMID: 22436456; PMID: 26470845). In patients with myeloid malignancies, ASXL1 mutations are mostly heterozygous frameshift or nonsense mutations that result in C-terminal truncation (PMID: 30982744; PMID: 26095772; PMID: 32683582; PMID: 29643185).
Protocols
Product Specific Protocols | |
---|---|
WB protocol for ASXL1 antibody 16803-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |